{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-020562","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2026-06-15T10:23:55+00:00","discovered_at":"2026-06-15T10:25:00.362231+00:00","generated_at":"2026-06-15T10:25:09.345233+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M","bullets":["Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).","Plan term extended through January 31, 2030; repricing of options/SARs explicitly prohibited without stockholder approval.","Three directors elected: Richard J. Barry, Pierre Gravier, Claude Nicaise, M.D. (each ~8.9M for, ~1.5M withheld, ~14.1M broker non-votes).","Ernst & Young ratified as auditor for FY2026 (22.7M for, 1.4M against). Non-binding say-on-pay passed (7.5M for, 2.8M against).","51% of outstanding shares (24.6M of 48.3M) represented at the meeting, constituting a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-020562","json":"https://secwatch.observer/filing/0001437749-26-020562.json","markdown":"https://secwatch.observer/filing/0001437749-26-020562.md","text":"https://secwatch.observer/filing/0001437749-26-020562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/sava20260610_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T10:25:09.345233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"594639ae02927e9c8d369a38d53f2fdbeec923a1","claim":"FILANA THERAPEUTICS, INC. shareholders approved Amendment to the 2018 Omnibus Incentive Plan at the 2026-06-11 meeting.","evidence_excerpt":"Proposal Two – An amendment to the Company’s 2018 Omnibus Incentive Plan was approved based upon the following votes: For Against Abstain Broker Non -Vote 8,427,565 1,869,290 118,621 14,144,300","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"8aa628841138470f5312785715300b7e615051a1","claim":"FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2026-06-11 meeting.","evidence_excerpt":"Proposal One – Three (3) nominees for election or re-election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Richard J. Barry 8,851,285 1,564,191 14,144,300 Pierre Gravier 9,069,595 1,345,881 14,144,300 Claude Nicaise, M.D. 8,924,355 1,491,121 14,144,300","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"8cc7145d6d4c0a6d4b96dd253ab675ddd58e3909","claim":"FILANA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-11 meeting.","evidence_excerpt":"Proposal Three – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026, was ratified based upon the following votes: For Against Abstain 22,671,610 1,408,513 479,653","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"d1538e6f7e147c02ce51a516832c18a3c2262342","claim":"FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.","evidence_excerpt":"Proposal Four – The 2025 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 7,487,142 2,827,840 100,494 14,144,300","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}